Vanguard Group Inc. Has $87.82 Million Stake in Xeris Biopharma Holdings, Inc. $XERS

Vanguard Group Inc. lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 13.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,186,677 shares of the company’s stock after purchasing an additional 1,358,760 shares during the period. Vanguard Group Inc. owned 0.07% of Xeris Biopharma worth $87,815,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Qube Research & Technologies Ltd raised its position in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Millennium Management LLC raised its position in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the last quarter. UBS Group AG raised its position in Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after buying an additional 1,554,869 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Xeris Biopharma by 38.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,698,757 shares of the company’s stock valued at $13,828,000 after buying an additional 470,798 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Xeris Biopharma

In other news, Director James Aloysius Brady sold 10,834 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the director directly owned 89,166 shares of the company’s stock, valued at $493,979.64. This trade represents a 10.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173 shares of the company’s stock, valued at approximately $7,433,467.79. This represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 60,835 shares of company stock valued at $367,860. Insiders own 6.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on XERS shares. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma presently has an average rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Trading Up 2.7%

NASDAQ XERS opened at $6.43 on Thursday. The firm has a market capitalization of $1.11 billion, a P/E ratio of 107.17 and a beta of 0.85. The business has a fifty day simple moving average of $5.91 and a 200 day simple moving average of $6.88. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.